AVEO PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 115
- Market Cap
- -
- Website
- http://www.aveooncology.com
Clinical Trials
86
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (62 trials with phase data)• Click on a phase to view related trials
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Conditions
- Metastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 410
- Registration Number
- NCT06064877
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Los Angeles, Westwood, California, United States
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05865535
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Lakewood, California, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT04987203
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Chao Family Comprehensive Cancer Center, UC Irvine, Irvine, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
A Phase 1 Study of AV-380 in Healthy Subjects
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04815551
- Locations
- 🇺🇸
Biotrial Inc., Newark, New Jersey, United States
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: Ficlatuzumab
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Registration Number
- NCT04100330
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Hepatocellular Carcinoma: Over 90 Companies Pursue Novel Therapies
Over 90 pharmaceutical and biotech companies are actively developing more than 95 pipeline drugs for hepatocellular carcinoma (HCC).